48.95USD-4.04%Mkt Cap: 7.06B USDP/E: —Last update: 2026-06-01
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-spari…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap7.06B USD
Enterprise Value5.80B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-766.63M USD
Revenue/Share—
Last Price48.95 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees507
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.93
PEG—
EV/EBITDA-5.41
EV/Revenue—
P/S—
P/B2.48
EPS (TTM)-6.89
EPS (Forward)-7.42
52W Range
29.0855% of range65.00
52W High65.00 USD
52W Low29.08 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.55%
ROA-25.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-655.58M USD
CapEx (TTM)56.97M USD
FCF Margin—
FCF Yield-6.23%
Net Debt-1.62B USD
Net Debt/EBITDA1.51
Balance Sheet
Debt/Equity0.04
Current Ratio7.49
Quick Ratio7.18
Book Value/Sh20.76 USD
Cash/Share12.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)109.00 USD
Target Range67.00 USD – 163.00 USD
# Analysts9
Ownership
Shares Out.144.40M
Float131.96M
Insiders0.53%
Institutions114.57%
Short Interest
Short Ratio9.6d
Short % Float9.60%
Short % Out.9.55%
Shares Short13.79M
Short (prev mo.)14.36M
Technical
SMA 5056.12 (-12.8%)
SMA 20047.88 (+2.2%)
Beta1.30
S&P 52W Chg27.70%
Avg Vol (30d)1.42M
Avg Vol (10d)1.63M
Technical Indicators
RSI (14)43.1
MACD-2.1125
MACD Signal-2.2375
MACD Hist.+0.1250
BB Upper58.93 USD
BB Middle52.11 USD
BB Lower45.29 USD
BB Width26.17%
ATR (14)2.235 USD
Vol Ratio (20d)0.37x